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Background: Over the past 2 decades new and key randomised controlled trials have 
reported the efficacy, clinical and cost effectiveness of psychological and 
pharmacological treatments for adolescents with major depression.  
Methods The literature was searched through pubmed, psychinfo , scopus and web of 
science for randomised controlled trials of current major depression together with 
meta-analyses and systematic reviews of trials between 2000-2017. Those specific to 
the adolescent years (11-18 years) were taken as the primary source for this narrative 
review. Additional selected studies in adults were used to illustrate methodological 
issues. 
Results: Manualised psychological therapies and the SSRI fluoxetine are more effective 
than active placebo in the treatment of major depressions. Mild to moderate illnesses 
attending community-based services are likely to benefit from psychological treatment 
alone. Moderately to severely ill patients attending clinic and hospital services are likely 
to benefit from monotherapies or combining psychological and pharmacological 
treatment. Antidepressants carry a small but significant side-effect risk including 
increased suicidality. Side effects from psychotherapies are somewhat lower but specific 
negative consequences remain less well characterised. There is some evidence that CBT-
based approaches prevent onset of major depression episode in well adolescents at 
high-risk. Other psychological interventions have not been adequately studied. There 
has been only limited identification of treatment moderators and no clear 
understanding of therapeutic mechanisms.  
Conclusions: There is now a range of clinically-effective treatments for depressed 
adolescents. Future research needs to reveal moderators of and mechanisms for 
individual differences to treatment response, determine psychotherapies of value for 
milder depressions, enhance our understanding of safety and side-effects for all 
treatments, and consider how to reduce and treat treatment-resistant cases.  
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Introduction  
This practitioner review considers the current state of knowledge regarding the 
treatment and prevention of major depressive episodes in adolescents. 
 
Selection Criteria for studies used in this review 
The literature was searched through pubmed, psychinfo, scopus and web of science for 
randomised controlled trials of current major depression and prevention of clinical 
depressions across the lifecourse together with meta-analyses and systematic reviews 
of trials of participants all between 2000-2017. Those specific and/or inclusive of the 
adolescent years (11-18 years) were taken as the primary source for this review. 
Additional studies in adults were used to illustrate methodological issues.  
  
The studies used in this review fulfilled the following criteria: 
Primary Treatment Studies: 
i) Adolescent patients with current interviewer-diagnosed DSM major 
depressive episode recruited into randomised controlled trials testing for 
treatment efficacy or effectiveness.   
OR 
Recruitment via self-reported depression symptoms or a history of affective 
disorder in parents into randomised controlled prevention trials.  
ii) Required a theory-based investigation with a declared a priori hypothesis 
that the nominated treatment of interest was superior (statistically and 
clinically significant) by end of study than the nominated control condition 
or no worse (not inferior to) than the nominated reference treatment.   
iii) RCT studies were planned with sample size estimates with a power of at 
least 80% and an alpha of 5%, this representing the current accepted 
tolerance for a false positive result. 
 
Reviews: 
Metanalyses and systematic reviews where studies described the search 
method and data analytic strategy according to accepted guidelines. 
 
As a result the major clinical scientific conclusions on treatment of a depressive episode 
are drawn from the 4 key randomised controlled trials reporting psychological and 
pharmacological treatments for depressed adolescents (March, Silva et al. 2004, 
Goodyer, Dubicka et al. 2007, Brent, Emslie et al. 2008, Goodyer, Reynolds et al. 2017).   
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In addition there are a set of studies on preventing the incident onset of major 
depression (Garber, Clarke et al. 2009 , Stallard, Sayal et al. 2012, Richardson, Ludman et 
al. 2014, Brent, Brunwasser et al. 2015).  We also utilise results of 6 meta-analyses and 
systematic reviews (Hetrick, Cox et al. 2015, Cipriani, Zhou et al. 2016, Hetrick, Cox et al. 
2016, Weersing, Jeffreys et al. 2017, Weisz, Kuppens et al. 2017, Werner-Seidler, Perry 
et al. 2017). The papers that are core to this review are described in tables one and two. 
 
Tables one and two here 
 
Designing Trials for studies of adolescent depression 
 
Samples and selection criteria 
Current patients have been recruited from hospitals, child and adolescent mental health 
clinics, independent practice, primary care settings and schools and directly from the 
population. Inclusion criteria varied between studies: for example, the Treatment of 
Adolescent Depression Study (TADS) study excluded acutely suicidal and psychotic 
patients at recruitment whereas the Adolescent Depression and Psychotherapy Trial 
(ADAPT) included such patients (March, Silva et al. 2004, Goodyer, Dubicka et al. 2007).  
Prevention or early intervention use schools and community clinics as recruitment sites. 
Cluster designs are preferred in which intact social units or clusters of individuals (eg 
school classes or year groups) are randomly allocated to intervention groups (Werner-
Seidler, Perry et al. 2017).  
 
Effect sizes and p values from RCTs 
How best to understand trials results is not determined by the significance of results 
alone. A very large influence on the p value (conventionally taken as 0.05) reporting 
statistical significance is sample size; the p value is also affected by the choice of 
measures, design and analytic procedures (Kraemer and Blasey 2015).  Failure to find a 
‘significant’ p value may mean there is no true difference between treatments or that 
there is a difference but that the study was underpowered.  It does not mean that there 
is definitely no difference.  
 
From the therapeutic perspective, the effect size (ES) is perhaps a more useful statistic 
than the p value. When there are continuous results (such as final scores on a self-rating 
questionnaire) Cohen’s d, also known as standardized mean difference, or the more 
conservative Hedges g  is reported which gives the degree of overlap of the distributions 
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of the scores, with consensus-agreed thresholds to interpret it. An effect size reported 
for dichotomous results (such as recovered vs non-recovered) is the success rate 
difference (SRD – probability of recovered in the active treatment group minus 
probability recovered in the control group). The number needed to treat (NNT) equals 
1/SRD. The NNT answers the question: How many patients must be treated with an 
intervention to get one more recovered compared to if they are all given a control 
treatment? Too small a sample size is a major reason for statistically non-significant 
findings and a common flaw making many treatment studies uninterpretable. 
Combining small trial results and looking for effects through pooling data and 
conducting meta-analyses is one method for combating lack of sample size.  
 
Placebo, nocebo and their effects in trials   
There is growing evidence that ‘placebo’ has active effects expressed through 
psychological and neural changes (Kaptchuk and Miller 2015). Such effects may operate 
through expectancy and beliefs about therapy prior to or as a consequence of 
randomisation. The placebo response in the best designed trials across the lifecourse 
report active placebo rates of around 30%-35% (Walkup 2017). This implies that 
treatment response greater than 35% effectively consist of active placebo+ active 
treatment.  
 Less research has been devoted to the nocebo effect: when a negative expectation 
causes a control condition to have a more negative outcome than it otherwise would.  In 
medicine overall it has been estimated that between 4 and 26% of patients who are 
randomly assigned to placebos in trials discontinue their use because of perceived 
adverse effects (Kaptchuk and Miller 2015). There have been no studies of the nocebo 
effect in treatment trials of depressed adolescents.  
 
Are there effective treatments for depressed adolescents? 
 
Psychological Therapies 
Although early RCT reports of CBT and IPT (interpersonal psychotherapy) reported 
results in favour of the specialised treatment the standardised mean difference is now 
reported as around 0.29, a ‘small’ effect size when compared to their active control 
groups (Weisz, Kuppens et al. 2017 ). This may be due to a combination of improved 
methodological rigour and better active control treatments. A recent metanalysis does 
confirm however that both CBT and IPT are efficacious and clinically effective 
(Weersing, Jeffreys et al. 2017). The number (n=6) and small sample size of IPT studies 
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and that CBT effects may be attenuated in clinically complex samples warrant positive 
but cautious interpretation of results to date.   
The IMPACT study (results of which were not included in the above metanalyses) is the 
most recent pragmatic effectiveness trial. The study compared psychological treatments 
for depressed adolescents attending specialist UK NHS CAMHS clinics (Goodyer, 
Reynolds et al. 2017). Two theory driven specialist therapies, CBT and short term 
psychoanalytic therapy (STPP) were evaluated against a pragmatic reference treatment 
termed brief psychosocial intervention (BPI: described below). The study was 
sufficiently powered (n=465) to be the first to examine whether specialist therapies 
delivered by highly trained personnel would exert therapeutic gains over and above 
those expected from a relatively simple active approach delivered via a manual by 
psychiatrists and mental health nurses in CAMHS. The critical value of IMPACT was the 
demonstration that CBT was not superior to STPP and that surprisingly, all three 
psychological treatments were as clinically effective as each other by both end of 
treatment and at 12 months post treatment follow up. We did not plan to test for 
statistical equivalence of CBT or STPP with BPI, so we cannot infer that they are 
clinically equivalent for all patients. Further the absence of a placebo control group in 
the study means improvements during or post-treatment may be due in part or whole to 
time alone.  
 
BPI for depressed adolescents: a brief outline   
BPI used in IMPACT consisted of psychoeducation, action-oriented, goal-focused, and 
interpersonal activities but did not use cognitive or analytic techniques. The 3 core 
principles underpinning BPI are: i) a collaborative approach; ii) selected use of 
behavioural activation techniques iii) subsequent instigation of recovery support 
methods. For experienced mental health professionals BPI training is 1 day with a 
second day for refection and clarification, plus ongoing supervisions in groups. The 
treatment duration was planned as up to eight individual sessions with up to 4 family 
sessions over 20 weeks. There is prior evidence that brief psychosocial interventions 
are efficacious for mild to moderate depression and anxiety disorders in both 
adolescents and adults (Klerman, Budman et al. 1987). The BPI method used in IMPACT 
needs replication and testing in the community to determine its value in non-clinic 
settings. 
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Attachment-Based Family Therapy 
Traditional structural systemic family therapy has no reported therapeutic effects for 
the treatment of depressed adolescents (Weersing, Jeffreys et al. 2017). Recently 
however an attachment-based family therapy model (ABFT) has been tested and does 
show potential therapeutic effects (Diamond, Russon et al. 2016). ABFT capitalises on 
the innate, biological desire for meaningful and secure relationships and prioritises 
relational processes as a treatment focus. The therapy provides an interpersonal, 
process-oriented and trauma-focused approach to treating adolescent depression, 
suicidality, and trauma. Further trials are needed to determine if this approach is as or 
more effective than other evidence based therapies.  
 
Side effects of psychological treatments 
Side effects of psychological therapies are less well investigated than those for SSRI 
medications (see below). When measuring side effects in TADS (such as increase in 
irritability, agitation and hazardous behaviours) associated with medication these were 
attenuated when both CBT and an SSRI are delivered concurrently (March, Silva et al. 
2004).  There was no such attenuation however for combination therapy in the TORDIA 
study for depressed patients who were pharmacotherapy resistant nor indeed between 
treatment arms for the IMPACT and the ADAPT studies. Currently we lack data on 
putative unique side effects accruing directly from psychological therapies (Linden 
2013, Jonsson, Alaie et al. 2014).  
  
Antidepressants and therapeutic effects 
Considering good methodological trials of depressed adolescents with a rigorous 
level of measures and monitoring gives efficacy rates some 20-25% greater than 
placebo (Walkup 2017).  The strongest current evidence for efficacy is for 
fluoxetine.  Sertraline and escitalopram have also been shown to be more 
effective than placebo  whereas other SSRIs, mirtazapine and venlafaxine have not 
been found to be different from placebo. (Cipriani, Zhou et al. 2016, Hetrick, Cox et al. 
2016). The TADS study showed that fluoxetine gave a standardised mean difference = 
0.51, a moderate to good effect indicating that 69% off those patients were below the 
mean depression score of the control group.  Future pharmacotherapy trials should 
consider recruiting more severe depressed cases to reduce the incidence of active 
placebo response more associated with milder disorders as this will provide a more 
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adequate test of efficacy or effectiveness of medication alone (Bridge, Birmaher et al. 
2009). 
 
Side effects of fluoxetine and other antidepressants 
Suicidal thoughts are more common in depressed adolescents prescribed an SSRI than 
those prescribed placebo (Bridge, Iyengar et al. 2007). The pattern of suicide attempts 
before and after starting medication are however equivalent in those starting fluoxetine 
with the highest prevalence being just before starting medication and declining 
thereafter (Simon and Savarino 2007). The rare emergence of disinhibition and 
switching to mania from depressed mood may be higher amongst depressed 
adolescents than adults treated with fluoxetine (Baldessarini , Faedda et al. 2013).  
These switches may occur up to 24 months following the onset of treatment with 3% of 
depressed patients receiving a diagnosis of bipolar disorder and a further 5% reporting 
mania like symptoms within 5 years of their unipolar depression. There is no clear 
evidence that the ‘switch’ is brought about by antidepressants; it may reflect the natural 
emergence of mania in an already at-risk population. Manic symptoms at presentation 
in depressed adolescents are however associated with a poor response to treatment 
(Maalouf, Porta et al. 2012). 
 
Cost-effectiveness of treating depressed adolescents 
Cost-effectiveness analysis is expressed as a ratio between gain in health (measured in 
improved symptoms or quality of life) and the direct (cost of therapy/treatment and 
hospital visits) and indirect (time off work, other additional clinic or hospital visits) 
costs associated with treatment. Treatments with lower cost but known clinical 
effectiveness may gain greater traction or ‘willingness to pay’ from service funders. 
Alternatively, ‘willingness to pay’ may be acceptable if the cost to the taxpayer or service 
provider generated by such patients is diminished as a consequence (pay now save 
later).  The IMPACT study reported treatment cost of approximately £1500 per patient  
(Goodyer, Reynolds et al. 2017). The ADAPT study noted that adding CBT to fluoxetine + 
specialist clinical care was not cost-effective (Byford, Barrett et al. 2007).  The TADS 
study reported that fluoxetine was more cost-effective than combination therapy or CBT 
after 12 weeks of treatment (Domino, Burns et al. 2008). By 36 weeks however cost-
effectiveness acceptability curves indicated that combination treatment was highly 
likely (>90%) to be more cost-effective than fluoxetine or CBT alone (Domino, Foster et 
al. 2009).  The TORDIA study showed that combined treatment decreases the number of 
days with depression but is costlier (Lynch, Dickerson et al. 2011). Here willingness to 
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pay should be positively influenced by the treatment gains and the possibility of cost 
reductions in the future.  
 
Therapeutic and clinical course 
Treatment response 
Improvements in first-episode or treatment-naïve depressed adolescents are often 
relatively rapid, with around a 25%-30% reduction in symptoms and improved 
psychosocial functioning over the first 12 weeks. Around 50%-60% of patients with a 
failed SSRI treatment show good response to combination treatment in the first six 
weeks (Emslie, Mayes et al. 2010). On average clinical remission (no diagnosis and/or a 
persistent 50% reduction in baseline symptoms) is maintained in some 80% of trial 
patients up to a year after end of treatment (Kennard, Silva et al. 2009, Goodyer, 
Reynolds et al. 2017).  Overall clinical progress monitoring should be continued beyond 
diagnostic change per se until there is a least a 50% drop in symptoms and 
improvements in function perhaps for at least another 6 months post treatment.  
Booster psychological treatment sessions may be advisable in those with increasing 
symptom during follow up and a ‘manage your lifestyle programme’ may be advised. For 
those patients who have responded clinically to fluoxetine, medication reduction should 
be undertaken with caution and probably not started until there has been at least 6 
months stable remission (no longer meeting diagnostic criteria and/or <50% of baseline 
pre-treatment symptoms).   
 
Treatment non-response  
Non-response may occur in up to 40% of depressed adolescents. Thus, non-responsive 
cases should subsequently receive combination treatment (eg CBT+SSRI).  Such a 
combination may reduce relapse in adolescents who received fluoxetine alone as a first 
line treatment (Emslie, Kennard et al 2015). Overall treatment response to combination 
therapies maybe associated with a greater risk reduction for subsequent relapse but this 
has yet to be fully established using a large enough trial of patients currently in 
remission (Curry, Silva et al. 2011, Clarke, Mayo-Wilson et al. 2015).  
Furthermore around 35% or so of depressed teenagers may drop out of a priori planned 
treatments, without agreement with the therapist thereby serving an early warning for 
putative non-response (Warnick, Gonzalez et al. 2012).  The IMPACT study reported that 
poor therapeutic alliance and missed sessions early (eg first month) may index later 
drop out  (O'Keeffe, Martin et al. 2017).  
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Risk of recurrence or relapse 
The likelihood of recurrence and relapse is 50%-75% for successfully treated patients 
(Kennard, Silva et al. 2009, Vitiello, Emslie et al. 2011). Recurrence can begin within a 
year implicating the need for greater attention to post-recovery rehabilitation 
programmes than given hitherto.  
 
Predictors, Moderators, Mediators And Mechanisms Of Treatment Response 
 
Predictors 
 There are no demographic factors that reliably predict differences in outcome. In 
contrast, clinical severity at baseline may be associated with poor treatment response. 
These include higher levels of depression symptoms, poor global functioning, high levels 
of suicidality, comorbid anxiety, cognitive distortions, hopelessness, and family conflict 
(Weersing, Jeffreys et al. 2017). 
 
Moderators 
A variable is established as a moderator of treatment response by testing for statistical 
interactions with two or more treatment options (Brookes, Whitely et al. 2004). In 
TADS, combined fluoxetine+CBT improved the outcome for mild-moderate depressions 
but not more severely ill patients (Curry, Rohde et al. 2006). Also from the TADS study, 
adolescents from high income families responded as well to CBT alone as to combined 
treatment.  In TORDIA, the addition of CBT was more effective in adolescents with more 
co-morbid disorders (Asarnow, Emslie et al. 2009).  Further, in TADS greater self-
reported cognitive distortions (catastrophizing, overgeneralization, personalization, and 
selective abstraction) positively moderated in favour of combined treatment over 
fluoxetine alone but did not moderate the difference between CBT alone and placebo 
(Curry, Rohde et al. 2006). There was a marginal positive moderator effect in TORDIA 
for hopelessness in favour of combined (SSRI+CBT) treatment over monotherapy alone 
(Asarnow, Emslie et al. 2009). Finally a history of child maltreatment moderates a 
poorer response to psychological treatments in studies of both treatment naïve 
and treatment resistant patients (Nanni, Uher et al. 2012).  
 
Mediation and mechanisms  
 Mediation analysis formally tests measures that may index the processes and 
mechanisms of the effect of interventions. To date only studies involving CBT have 
undertaken mediation analyses to determine if therapy altered negative cognitive 
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biases. Depressogenic thoughts, as indexed by measures of dysfunctional attitudes, 
negative automatic thinking, cognitive ruminations and negative behavioural styles have 
all shown some promise as potential mediators, (Kaufman, Rohde et al. 2005, Stice, 
Rohde et al. 2010). Three factors make any conclusions problematic: first the mediation 
measures have all been self-reported making a marked confound between antecedent 
processes and current symptoms; second mediation analyses require temporal 
separation of the measures for cognitive-behavioural change and symptoms which has 
not yet occurred; third comprehensive measurement with little or no missing data is 
required. No study has overcome these problems and had sufficient power and sample 
size to give valid and replicated findings.  There are no mediation studies reported 
specifically for any SSRI. Mediators may also be revealed in measures of patient 
treatment expectation and experience such as readiness or motivation to change but 
this has yet to be tested  (Lewis, Simons et al. 2009). Overall there are currently no 
substantive findings that reveal how psychological or pharmacological treatments 
mediate outcome. 
 
Prevention of Major Depression  
Ideally prevention is better than cure but currently there is no clear-cut strategy that 
reduces incident onset of depression in the population at large (Stallard, Sayal et al. 
2012,  Werner-Seidler, Perry et al. 2017). What evidence there is supports a targeted 
approach aimed at high risk adolescent groups rather than a universal approach 
delivered to all adolescents with non-clinical but elevated symptoms (Garber, Clarke et 
al. 2009). Interestingly this program was least effective where there was a currently 
depressed parent during the treatment. Further long-term effects were maintained by 
occasional booster sessions to the vulnerable offspring (Brent, Brunwasser et al. 2015).  
 
Issues and Prospects 
Behavioural phenotypes and clinical response 
There is growing evidence that the manifest characteristics of affective disorders and 
their comorbidities emerge from a common underlying general latent distress-
psychopathology trait, a P factor as it were, where higher P scores reflect the increasing 
liability for a set of particular clinical signs and symptoms and hazardous behaviours 
(Brodbeck, Goodyer et al. 2014, Stochl, Khandaker et al. 2015). These bifactor 
approaches also reveal specific factors independent of each other such as restlessness-
fatigue and hopelessness-suicidality. Whether a bi-factorial phenotype will provide 
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more precision in revealing clinical moderator typologies of treatment remains to be 
determined. 
 
Adaptive designs  
An integrated modular design has been suggested as a more effective alternative to 
delivering a single treatment modality for mentally ill children and adolescents.  The 
method allows a flexible application of treatments with known efficacy for specific 
disorders (depression, anxiety, conduct disorder) fitted within a collaborative design. 
Treatment outcomes were better when compared to usual care (Weisz, Choprita et al. 
2012). This modular approach can be viewed as a forerunner of adaptive design which 
are trials designed to identify which patients are most likely to derive benefit from a 
particular therapy (Drazen, Harrington et al. 2016). Differing somewhat from the 
aforementioned modular approach treatments run in sequence with patients who fail a 
first treatment moving forward to a second treatment and then a third if the second fails 
and so on (figure one).  
 
Figure One Here. 
 
Before the trial a predefined operational level of clinical improvement is set that results 
in stoppage of treatment (remission). The trial implementation only considers the % of 
non-responders as those who have not stopped by end of the treatment sequence not 
just phase 1. The statistics are more complex but the results define what treatments 
work best for which patients.  
 
Treatment Guidelines For Practitioners 
Current evidence supports a collaborative care approach throughout the treatment 
period. The evidence base for the treatment of mild depressions is rather equivocal: 
patients with relatively simple and mild depressions should receive a psychosocial 
treatment and not receive antidepressants. For moderate to severe and/or complex 
depression, the decision is not straightforward, as psychological therapies and 
fluoxetine have advantages and disadvantages.  A first line therapy can be a 
psychological treatment but more severe and complex depressed patients with 
comorbidities, psychotic phenomenon suicidal and self-harming behaviours should be 
rapidly assessed for fluoxetine and psychosocial treatment in combination. In some 
cases, young people and their families may, after full explanation of the options, prefer 
antidepressants over talking therapy.  In such cases, antidepressants as monotherapy 
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are justified by the evidence.  A framework for clinical assessment, treatment and 
monitoring for depressed adolescents is shown in Figure 2.  
 
Figure two here 
  
 
Limitations 
This is a selected narrative review and the potential effects of studies not included here 
cannot be gauged. Many studies that tested the efficacy of antidepressants excluded 
adolescents with suicidality and most co-morbid disorders, making it especially hard to 
generalise study results to severe and complex cases. The dominance of CBT principled 
programmes (>85%), makes comparisons between different psychological treatments 
problematic especially in community and schools based programmes.  
 
 
Key Practitioner Message 
 
 Major depression episodes are highly treatable and active therapies are more 
effective than active placebos alone.  
 
 Brief psychosocial therapies, regardless of theoretical orientation, are associated 
with clinical improvement within 12 weeks in some 70% of cases.   
 
 For complex depression fluoxetine is more effective than placebo, and may be 
more acutely effective than CBT. There is a greater risk of side-effects (in 
particular suicidality) which make fluoxetine alone less appropriate than 
combination therapy as a first-line. 
 
 Lack of response to first-line treatments should lead to combination 
pharmacological and psychological treatment being offered. 
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Areas for future research 
 
 Reformulating the clinical phenotype to improve the clinical decision making. 
 
 Urgent investigation of moderator and mediator mechanisms. 
 
 Treatment resistance is in need of considerable further clinical research. 
 
 Clearer evidence required for preventative interventions. 
 
 Evaluating side effects and adverse effects of psychological treatments is long 
overdue.  
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Table One Randomised Clinical Trials 
 
Authors Trial 
Type 
Setting and Target 
Population 
Sample 
Characteristics 
Treatment Main outcome 
measures  
Outcome 
i) Randomised Controlled Trials  
March,  Silva, et 
al.(2004) 
RCT 
 
Volunteer sample. 
13 US academic and 
community clinics 
 
12-17 yrs 
N= 439 
MDD 
12 wks duration  
 
4 treatment groups  
1.Fluoxetine alone (10 
to 40 mg/d). 
2. CBT alone. 
3. CBT with fluoxetine 
(10 to 40 mg/d)  
4.placebo (equivalent to 
10 to 40 mg/d).  
 
1. Reduction in CCDRS-
R total score. 
 2. CGI improvement 
score of 2 or less. 
CBT+ fluoxetine and fluoxetine alone 
both superior to placebo and CBT 
alone.  
 
For CBT+ fluoxetine over control: 
es = 0.86  
NNT = 3 
 
Goodyer, Dubicka et al.  
et al (2007) 
RCT Clinic-recruited sample 
6 NHS CAMHS 
 
11-17yrs 
n=208 
 
Major or probable 
major depression. 
 
2 arm design 
12 weeks duration. 
 
1.SSRI + care  
 
2.SSRI+ care+ CBT.  
 
1.Reduction in 
HoNOSCA total score. 
2.Reduction in self 
reported depressive 
symptoms. 
 
No added value for additional CBT in 
patients already receiving 
psychosocial care + fluoxetine    
Brent, Emslie et al 
(2008) 
RCT  6 US academic and 
community clinics. 
 
Treatment resistant 
sample. 
n=334 patients 12 to 18 
years  
 
Primary diagnosis of 
MDD with no response 
to 8 wks SSRI. 
 
Twelve wks switch to:  
1. A different SSRI 
(paroxetine, citalopram, 
or fluoxetine, 20-40 
mg). 
2. A different SSRI+CBT.  
3. Venlafaxine (150-225 
mg).  
4. Venlafaxine + CBT. 
1. CGI improvement. 
 
2. Decrease of > 50% in 
the CDRS-R. 
CBT+ another SRRI resulted in a 
higher rate of clinical response. 
 
es = 0.39 
NNT = 7 
  
Stallard, Sayal  et al. 
(2012)  
Cluster RCT Eight UK secondary 
schools.  
 
 
N= 1064  
Age 12-16 years. 
 
high self reported 
depression symptoms. 
 
3 treatments 
1.Group CBT 
2.Group attention 
control. 
3.usual school care 
Self-reported symptoms 
of depression at 12 
months.  
Outcomes were similar for attention 
control, usual school provision, and 
cognitive behavioural therapy.  
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Goodyer, Reynolds et al 
(2017) 
RCT 15 NHS CAMHS sites 
 
N=465 patients 
Age 11-17 years 
MDD 
 
3 treatment arms 
1.CBT 
2.STPP 
3.BPI 
Self reported 
depressive symptoms 
one year after the end 
of treatment. 
No overall superiority between the 
treatments.   
Garber, Clark et al 
(2009) 
RCT 
 
4 USA cities N= 316  
Age 13-17 years  
 
1.Offspring of parents 
with current or prior 
depressive illness. 
2. Adolescents had a 
past history of 
depression, current 
elevated depressive 
symptoms. 
 2 treatment arms: 
1.CBTprevent program  
2. Usual care alone. 
 
Probable or definite 
depressive episode. 
 
Depressive episodes were lower for 
CB prevent. 
es = 0.2  
NNT = 9  
 
Richardson, Ludman et 
al. (2014) 
RCT 
 
Nine primary care 
clinics 
 
N= 101  
Age 13-17 years 
 
Screen positive for 
depression on 2 
occasions  
or  MDD 
2 arms: 
1. Collaborative care  
2. Usual care  
 
Change in depressive 
symptoms on CDRS-R; 
at 12 months.  
Intervention youth had greater 
decreases in CDRS-R scores. 
 
es = 0.71 
NNT = 4 
Weersing, Brent et al. 
(2017) 
 
 
 
 
RCT 
 
 
9 paediatric clinics in 2 
cities in the USA  
 
N=185  
Age 8.0-17 years 
Full or probable 
diagnoses of anxiety 
and/or depressive 
disorders 
2 treatment arms: 
 
1.Brief behavioural 
therapy (BBT). 
2. Assisted referral to 
care. 
1. CGI improvement 
score of 2 or less.  
clinical improvement greater in BBT 
group (56.8% vs 28.2%) 
 
es = 0.58  
NNT = 4,  
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Table Two:  Reviews and Metanalyses 
Authors Study 
Type 
Target 
Population 
Study 
Characteristics 
Investigation Purpose  Main outcome 
measures  
Outcome 
Hetrick, Cox, Merry 2015 Meta-analysis RCTs N=18,253 
43 studies  
Age 5-19 years 
 
 
Published or unpublished 
individual and cluster RCTs. 
 
 
 
Efficacy of prevention 
programmes  
 
Reduction in 
depression diagnosis 
CBT has some 
effectiveness. Best 
with targeted 
populations.  
Fewer IPT studies but 
approach appears 
promising.  
Too few studies of 
other interventions. 
Cipriani, et al. 2016 Network meta-analysis  34 trials eligible. 
N= 5260  
Age 6-18 years 
14 antidepressant 
treatments.  
Efficacy of 
antidepressant’s  
Reduction in 
depressive symptoms. 
 
Only fluoxetine was 
more effective than 
placebo. 
Hetrick, Cox et al 2016. Systematic review  N=13,829 
participants  
 
Aged 5-19 years 
 
 
Psychological prevention 
interventions. 
Preventing the onset of 
depressive disorder. 
 
Reduced depression 
symptoms  
Not enough evidence 
to support the 
implementation of 
depression prevention 
programmes.   
 
Weersing, Jeffreys  et al 
2017 
Narrative review N = 2659  
N=42 studies 
Age =  13-24 years  
(mean <18)  
 
 
 
Psychological  treatments  Efficacy and 
effectiveness of 
psychotherapies for 
existing depression. 
Primary outcome of 
i) reduction in 
diagnostic cases 
ii) reduction in 
depressive symptoms 
below clinical cut off. 
CBT possibly 
efficacious. 
IPT promising. 
No other psychological 
treatment is studied 
well enough. 
 
Weisz, Kuppens et al 2017 
 
Metanalysis N=447 studies  
N=30,431 
participants 
Age 6-18 years  
 
 
Psychological therapies  
 
youth internalizing and 
externalizing  
disorders. 
Efficacy and 
effectiveness of 
psychological  
treatment. 
Primary outcome of 
i)% reduction in 
diagnostic cases 
ii) reduction in 
depressive symptoms 
below clinical cut off. 
Behaviour Therapies 
and CBT showed 
similar and robust 
effects. 
ES =  0.29 
Usual care a potent 
comparison condition. 
 
 
Werner-Seidler,Perry et al 
2017 
Systematic review and 
Metanalysis  
N =31,794 
participants  
81 studies. 
Age 6-18 years 
Psychological prevention. Efficacy and 
effectiveness of in 
schools settings. 
depression symptom 
reduction  
Targeted programmes 
do better than 
universal.  
ES =  0.23  
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Key MDD: Major depressive Disorder; CDRS-R: Children’s depression rating Scale –revised ; CGI: Clinical global interview; NNT: Number needed to treat; RCT: randomized controlled 
trial: es: effect size (hedges g); CBT: Cognitive behaviour therapy; STT: Short term Psychoanalytic Therapy; BPI: Brief Psychosocial  Intervention; CBP: Cognitive Behaviour 
Programme; IPT: Interpersonal Therapy 
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